{"id":5650,"date":"2023-12-13T11:11:33","date_gmt":"2023-12-13T16:11:33","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5650"},"modified":"2026-04-13T13:12:50","modified_gmt":"2026-04-13T17:12:50","slug":"aptamarker-breaking-barriers-animal-trials-to-human-trials","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/es\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","title":{"rendered":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials"},"content":{"rendered":"<ul>\n<li><strong>Ventaja de Tolerancia Inmunol\u00f3gica de los Aptamarkers:<\/strong> Los Aptamarkers superan los problemas de tolerancia inmunol\u00f3gica en el desarrollo tradicional de anticuerpos.<\/li>\n<li><strong>Aptamarkers vs. Anticuerpos: Una Ventaja Cuantitativa:<\/strong> Un espectro de reconocimiento m\u00e1s amplio alinea el panorama de biomarcadores en modelos animales de manera m\u00e1s cercana con el contexto humano.<\/li>\n<li><strong>Entrenamiento de Aptamarkers en Ensayos con Animales:<\/strong> Los Aptamarkers pueden ser entrenados en ensayos con animales, facilitando el trabajo previo para los ensayos con humanos subsiguientes. Ajustar y optimizar los Aptamarkers en animales garantiza una transici\u00f3n m\u00e1s fluida a las aplicaciones humanas, reduciendo los desaf\u00edos imprevistos en los ensayos cl\u00ednicos.<\/li>\n<\/ul>\n<p>La traducci\u00f3n de descubrimientos biom\u00e9dicos de modelos animales a aplicaciones humanas es un puente cr\u00edtico en el viaje del desarrollo de medicamentos. La plataforma de Aptamarkers de NeoVentures Biotechnology emerge como una fuerza transformadora en este proceso, ofreciendo una soluci\u00f3n \u00fanica a los desaf\u00edos enfrentados en el desarrollo tradicional de anticuerpos. En este blog, profundizamos en las complejidades de traducir biomarcadores de animales a humanos, mostrando c\u00f3mo los Aptamarkers, con sus ventajas distintivas, est\u00e1n revolucionando este aspecto crucial de la investigaci\u00f3n biom\u00e9dica.<\/p>\n<h2>La Ventaja de Tolerancia Inmunol\u00f3gica de los Aptamarkers<\/h2>\n<p>El desarrollo tradicional de anticuerpos a menudo enfrenta desaf\u00edos relacionados con la tolerancia inmunol\u00f3gica, lo que limita la detecci\u00f3n de ep\u00edtopos ort\u00f3logos, es decir, las estructuras equivalentes entre especies. Los Aptamarkers, al carecer de tolerancia inmunol\u00f3gica, superan esta barrera, lo que les permite detectar un rango m\u00e1s amplio de ep\u00edtopos ort\u00f3logos. Esta caracter\u00edstica \u00fanica significa que los Aptamarkers pueden reconocer ep\u00edtopos que ser\u00edan eliminados durante el desarrollo de anticuerpos, lo que lleva a una capacidad de detecci\u00f3n de biomarcadores m\u00e1s amplia e inclusiva.<\/p>\n<h2>Aptamarkers vs. Anticuerpos: Una Ventaja Cuantitativa<\/h2>\n<p>La falta de tolerancia inmunol\u00f3gica en el desarrollo de Aptamarkers se traduce en una ventaja cuantitativa. En pocas palabras, m\u00e1s Aptamarkers pueden unirse a un biomarcador dado en comparaci\u00f3n con los anticuerpos. Esta abundancia de oportunidades de uni\u00f3n amplifica el potencial de traducci\u00f3n entre ensayos con animales y ensayos con humanos. El espectro de reconocimiento m\u00e1s amplio garantiza que el panorama de biomarcadores identificado en modelos animales se alinee m\u00e1s estrechamente con el contexto humano, proporcionando a los investigadores una base m\u00e1s precisa y traducible.<\/p>\n<h2>Entrenamiento de Aptamarkers en Ensayos con Animales<\/h2>\n<p>La versatilidad de los Aptamarkers va m\u00e1s all\u00e1 de sus capacidades mejoradas de detecci\u00f3n de biomarcadores. Los Aptamarkers pueden ser entrenados en ensayos con animales, lo que permite a los investigadores sentar las bases para ensayos humanos subsiguientes. Este enfoque proactivo permite una detecci\u00f3n temprana de los efectos del tratamiento, mejorando la eficiencia del proceso de desarrollo de medicamentos. La capacidad de ajustar y optimizar los Aptamarkers en modelos animales garantiza una transici\u00f3n m\u00e1s fluida a las aplicaciones humanas, reduciendo el riesgo de desaf\u00edos imprevistos durante los ensayos cl\u00ednicos.<\/p>\n<h2>La Plataforma Aptamarker: Una Nueva Ciencia<\/h2>\n<p>La plataforma Aptamarker representa un cambio de paradigma en el campo del desarrollo de biomarcadores. Como una nueva ciencia, abre puertas a posibilidades y aplicaciones innovadoras que alguna vez estuvieron limitadas por las restricciones de los m\u00e9todos tradicionales. Las caracter\u00edsticas \u00fanicas de los Aptamarkers invitan a la colaboraci\u00f3n y exploraci\u00f3n, alentando a los investigadores y socios a contribuir con sus pensamientos e ideas para ampliar los horizontes de esta tecnolog\u00eda transformadora.<\/p>\n<h2>Asociaciones Colaborativas para la Resoluci\u00f3n de Problemas<\/h2>\n<p>En NeoVentures Biotechnology, reconocemos el potencial de la plataforma Aptamarker y estamos dedicados a establecer asociaciones colaborativas. Invitamos a investigadores, cient\u00edficos y organizaciones a unirse a nosotros en la exploraci\u00f3n de las vastas aplicaciones de esta tecnolog\u00eda. El compromiso de trabajar colectivamente para aplicar los Aptamarkers en la resoluci\u00f3n de problemas del mundo real ejemplifica nuestra visi\u00f3n de un futuro donde la investigaci\u00f3n biom\u00e9dica avanza a trav\u00e9s del conocimiento compartido y soluciones innovadoras.<\/p>\n<h2>Liberando el Potencial de los Aptamarcadores<\/h2>\n<p>En conclusi\u00f3n, la traducci\u00f3n de biomarcadores de animales a humanos es una etapa fundamental en el desarrollo de medicamentos, y la plataforma Aptamarker de NeoVentures Biotechnology est\u00e1 pioneraando un enfoque transformador. Al aprovechar la falta de tolerancia inmunol\u00f3gica, la ventaja cuantitativa sobre los anticuerpos y la capacidad de ser entrenados en ensayos con animales, los Aptamarkers garantizan una transici\u00f3n sin problemas entre las fases precl\u00ednicas y cl\u00ednicas. Al embarcarnos en esta nueva ciencia, acogemos con entusiasmo la colaboraci\u00f3n para desbloquear todo el potencial de los Aptamarkers y remodelar el panorama de la investigaci\u00f3n biom\u00e9dica. Juntos, podemos abrir camino a un futuro donde soluciones innovadoras surjan de la convergencia de diversas perspectivas y tecnolog\u00edas de vanguardia.<\/p>","protected":false},"excerpt":{"rendered":"<p>Immune Tolerance Advantage of Aptamarkers: Aptamarkers overcome immune tolerance issues in traditional antibody development. Aptamarkers vs. Antibodies: A Quantitative Advantage: Broader recognition spectrum aligns the biomarker landscape in animal models more closely with the human context. Training Aptamarkers in Animal Trials: Aptamarkers can be trained in animal trials, facilitating groundwork for subsequent human trials. Fine-tuning&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/es\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/\" rel=\"bookmark\">Leer m\u00e1s &raquo;<span class=\"screen-reader-text\">Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":5652,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8,39],"tags":[],"class_list":["post-5650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers","category-case-studies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials<\/title>\n<meta name=\"description\" content=\"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/es\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\" \/>\n<meta property=\"og:description\" content=\"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/es\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T16:11:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T17:12:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\",\"datePublished\":\"2023-12-13T16:11:33+00:00\",\"dateModified\":\"2026-04-13T17:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\"},\"wordCount\":629,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"articleSection\":[\"Aptamers\",\"Case Studies\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\",\"name\":\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"datePublished\":\"2023-12-13T16:11:33+00:00\",\"dateModified\":\"2026-04-13T17:12:50+00:00\",\"description\":\"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"width\":1000,\"height\":800,\"caption\":\"dropper and Petry dish\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","description":"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/es\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","og_locale":"es_ES","og_type":"article","og_title":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","og_description":"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.","og_url":"https:\/\/neoaptamers.com\/es\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","og_site_name":"neoaptamers","article_published_time":"2023-12-13T16:11:33+00:00","article_modified_time":"2026-04-13T17:12:50+00:00","og_image":[{"width":1000,"height":800,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","type":"image\/png"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Gregory Penner","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","datePublished":"2023-12-13T16:11:33+00:00","dateModified":"2026-04-13T17:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/"},"wordCount":629,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","articleSection":["Aptamers","Case Studies"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","url":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","name":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","datePublished":"2023-12-13T16:11:33+00:00","dateModified":"2026-04-13T17:12:50+00:00","description":"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","width":1000,"height":800,"caption":"dropper and Petry dish"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/comments?post=5650"}],"version-history":[{"count":3,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5650\/revisions"}],"predecessor-version":[{"id":6499,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/5650\/revisions\/6499"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media\/5652"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media?parent=5650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/categories?post=5650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/tags?post=5650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}